This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sakko, A. J. Articles by Horsfall, D. J. Search for Related Content PubMed PubMed Citation Articles by Sakko, A. J. Articles by Horsfall, D. J.

Modulation of Prostate Cancer Cell Attachment to Matrix by Versican¹

Dame Roma Mitchell Cancer Research Laboratories, Hanson Institute, University of Adelaide, Adelaide, South Australia, 5000, Australia [C. R., K. M., S. S., W. D. T., D. J. H.]; Department of Surgery, Flinders Medical Research Institute, Flinders University School of Medicine, Adelaide, South Australia, 5042, Australia [A. J. S.]; Surgical Specialty Services, Royal Adelaide Hospital, Adelaide, South Australia 5000 [V. R. M.]; and Division of Life Sciences, Cell and Molecular Biology, University of Texas at San Antonio, San Antonio, Texas 78249 [R. G. L.]

In this study, we examined whether versican, a recognized anti-cell adhesive molecule for various mesenchymal and nerve cell types, influences prostate cancer cell adhesion to extracellular matrix components. Prostate cancer cell adhesion to fibronectin, a major component of the stromal extracellular matrix was inhibited by versican-rich conditioned medium (CM) from cultured human prostatic fibroblasts. In contrast, cancer cell attachment to laminin, a component of basement membranes, was not affected by the same CM. Consistent with versican being the active inhibitory factor in the CM, the integrity of chondroitin sulfate side chains and an ability to bind the RGD (Arg-Gly-Asp) peptide sequence of fibronectin were essential for the inhibition of prostate cancer cell attachment to fibronectin. Subsequent studies with versican purified from human prostate fibroblast CM confirmed its anti-adhesive activity. We conclude that versican is an important modulator of tumor cell attachment to the interstitial stromal matrix of the prostate, the latter being an essential step in cancer cell motility and local invasion of the prostatic stroma.

This article has been cited by other articles:

				C. Domenzain-Reyna, D. Hernandez, L. Miquel-Serra, M. J. Docampo, C. Badenas, A. Fabra, and A. Bassols Structure and Regulation of the Versican Promoter: THE VERSICAN PROMOTER IS REGULATED BY AP-1 AND TCF TRANSCRIPTION FACTORS IN INVASIVE HUMAN MELANOMA CELLS J. Biol. Chem., May 1, 2009; 284(18): 12306 - 12317. [Abstract] [Full Text] [PDF]

				A. J. Sakko, M. S. Butler, S. Byers, B. J. Reinboth, J. Stahl, J. G. Kench, L. G. Horvath, R. L. Sutherland, P. D. Stricker, S. M. Henshall, et al. Immunohistochemical Level of Unsulfated Chondroitin Disaccharides in the Cancer Stroma Is an Independent Predictor of Prostate Cancer Relapse Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2488 - 2497. [Abstract] [Full Text] [PDF]

				J. T. Read, M. Rahmani, S. Boroomand, S. Allahverdian, B. M. McManus, and P. S. Rennie Androgen Receptor Regulation of the Versican Gene through an Androgen Response Element in the Proximal Promoter J. Biol. Chem., November 2, 2007; 282(44): 31954 - 31963. [Abstract] [Full Text] [PDF]

				C. Ricciardelli, D. L. Russell, M. P. Ween, K. Mayne, S. Suwiwat, S. Byers, V. R. Marshall, W. D. Tilley, and D. J. Horsfall Formation of Hyaluronan- and Versican-rich Pericellular Matrix by Prostate Cancer Cells Promotes Cell Motility J. Biol. Chem., April 6, 2007; 282(14): 10814 - 10825. [Abstract] [Full Text] [PDF]

				M. Pukkila, A. Kosunen, K. Ropponen, J. Virtaniemi, J. Kellokoski, E. Kumpulainen, R. Pirinen, J. Nuutinen, R. Johansson, and V.-M. Kosma High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma J. Clin. Pathol., March 1, 2007; 60(3): 267 - 272. [Abstract] [Full Text] [PDF]

				V. U. Bai, A. Kaseb, S. Tejwani, G. W. Divine, E. R. Barrack, M. Menon, A. B. Pardee, and G. P.-V. Reddy Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine PNAS, February 13, 2007; 104(7): 2343 - 2348. [Abstract] [Full Text] [PDF]

				G. W. Yip, M. Smollich, and M. Gotte Therapeutic value of glycosaminoglycans in cancer. Mol. Cancer Ther., September 1, 2006; 5(9): 2139 - 2148. [Abstract] [Full Text] [PDF]

				X. Bao, T. Muramatsu, and K. Sugahara Demonstration of the Pleiotrophin-binding Oligosaccharide Sequences Isolated from Chondroitin Sulfate/Dermatan Sulfate Hybrid Chains of Embryonic Pig Brains J. Biol. Chem., October 21, 2005; 280(42): 35318 - 35328. [Abstract] [Full Text] [PDF]

				X. Zhao, K. E. Ramsey, D. A. Stephan, and P. Russell Gene and Protein Expression Changes in Human Trabecular Meshwork Cells Treated with Transforming Growth Factor-{beta} Invest. Ophthalmol. Vis. Sci., November 1, 2004; 45(11): 4023 - 4034. [Abstract] [Full Text] [PDF]

				M J Pukkila, A S T Kosunen, J A Virtaniemi, E J Kumpulainen, R T Johansson, J K Kellokoski, J Nuutinen, and V-M Kosma Versican expression in pharyngeal squamous cell carcinoma: an immunohistochemical study J. Clin. Pathol., July 1, 2004; 57(7): 735 - 739. [Abstract] [Full Text] [PDF]